First Turn Management LLC Has $12.37 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

First Turn Management LLC lessened its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 37.8% in the third quarter, Holdings Channel reports. The firm owned 67,942 shares of the company’s stock after selling 41,280 shares during the quarter. First Turn Management LLC’s holdings in Krystal Biotech were worth $12,367,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of KRYS. EFG Asset Management North America Corp. raised its stake in Krystal Biotech by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after acquiring an additional 60 shares in the last quarter. GAMMA Investing LLC raised its stake in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after acquiring an additional 93 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Krystal Biotech by 11.1% during the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after acquiring an additional 94 shares in the last quarter. Arizona State Retirement System raised its stake in Krystal Biotech by 2.1% during the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after acquiring an additional 108 shares in the last quarter. Finally, Fiera Capital Corp raised its stake in Krystal Biotech by 0.8% during the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after acquiring an additional 130 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $175.64 on Tuesday. The business’s 50 day simple moving average is $180.83 and its 200 day simple moving average is $181.79. Krystal Biotech, Inc. has a one year low of $99.00 and a one year high of $219.34. The stock has a market capitalization of $5.05 billion, a PE ratio of 99.23 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same period in the prior year, the business posted ($0.67) earnings per share. The firm’s revenue was up 879.9% on a year-over-year basis. As a group, research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on KRYS shares. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, November 5th. Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Evercore ISI boosted their price target on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Citigroup boosted their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $197.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).